GlassScriptPhysician profile
Tony T Lee
NPI 1477692416
$7,915.85
in general payments reported to CMS, 2019-2025
48 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $462 · 2021: $288 · 2022: $755 · 2023: $1,623 · 2024: $2,024 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,334.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.66 | 2022-2025 | |
| Neuronetics, INC. | $561.10 | 2019-2025 | Neurostar Tms Therapy System |
| Lilly USA, LLC | $424.92 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $389.46 | 2019-2025 | |
| Neurelis, INC. | $350.71 | 2022-2025 | Valtoco |
| Ucb, INC. | $337.57 | 2019-2025 | Rystiggo, Briviact |
| Neurocrine Biosciences, INC. | $335.84 | 2019-2023 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $319.29 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $316.77 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $294.16 | 2019-2025 | |
| Eisai INC. | $254.38 | 2024-2025 | |
| Genzyme Corporation | $209.84 | 2019-2022 | |
| Biogen, INC. | $194.37 | 2019-2025 | Vumerity, Tysabri |
| Boston Scientific Corporation | $180.04 | 2022-2025 | Vercise |
| Sunovion Pharmaceuticals INC. | $161.69 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.